Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development

The MarketWatch News Department was not involved in the creation of this content.

NEW YORK, Dec. 1, 2020 /PRNewswire via COMTEX/ —
NEW YORK, Dec. 1, 2020 /PRNewswire/ — Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced the appointment of Mary Mei Chen, M.D., Ph.D. to the position of Vice President of Clinical Development, effective immediately. In this role, Dr. Chen will lead the clinical development of Actinium’s CD33 program including the Actimab-A plus CLAG-M and Actimab-A plus venetoclax combination trials in relapsed and refractory Acute Myeloid Leukemia (“R/R AML”). Dr. Chen joins Actinium from GlycoMimetics, where she played a leading role in multiple clinical trials including the global pivotal Phase 3 study of uproleselan (GMI-1271-301). In addition to working on Actimab-A development, Dr. Chen will also utilize her training in immunology and experience in translational medicine to identify areas of synergy between targeted radiotherapy with

Read More